Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Mael HeibligMarcela A FerradaMatthew J KosterThomas BarbaMathieu Gerfaud-ValentinArsenne MekinianHenrique CoelhoGaelle FossardFiorenza BarracoLionel GalicierBoris BienvenuPierre HirschGuillaume VialAnne Blandine BoutinJoris GallandGuillaume Le GuennoAdrien BigotKenneth J WarringtonTanaz A KermaniPeter C GraysonBhavisha A PatelDavid B BeckYvan JamillouxPierre FenauxPierre SujobertPublished in: Blood (2022)
Keyphrases